Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proactive Management of Endoperitoneal Spread in Colonic Cancer
NCT02974556Phase 3Unknown
- Sponsor
- Sapienza University of Rome
- Start
- Mar 2024
- Primary completion
- Sep 2024
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin in colon cancer (2 arms), sponsored by Sapienza University of Rome. Primary endpoint: Incidence of endoperitoneal recurrence at 36 months. Status: unknown.
02
Drugs
oxaliplatin
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT02974556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02974556.